These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38185696)

  • 1. Effect of dolutegravir-based versus efavirenz-based antiretroviral therapy on excessive weight gain in adult treatment-naïve HIV patients at Matsanjeni health center, Eswatini: a retrospective cohort study.
    Mukuna DM; Decroo T; Nyapokoto CM
    AIDS Res Ther; 2024 Jan; 21(1):4. PubMed ID: 38185696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A retrospective clinical study of dolutegravir- versus efavirenz-based regimen in treatment-naïve patients with advanced HIV infection in Nanjing, China.
    Zhong M; Li M; Qi M; Su Y; Yu N; Lv R; Ye Z; Zhang X; Xu X; Cheng C; Chen C; Wei H
    Front Immunol; 2022; 13():1033098. PubMed ID: 36700216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of dolutegravir vs. efavirenz-based combined antiretroviral therapies in HIV-infected treatment-naive patients in a Nigerian treatment centre.
    Isah A; Chukwu PO; Abba A; Igboeli NU; Ebere A; Omotola OF; Alozie FA; Ekwunife OI; Adibe MO
    Afr Health Sci; 2023 Mar; 23(1):157-169. PubMed ID: 37545946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood glucose level and serum lipid profiles among people living with HIV on dolutegravir-based versus efavirenz-based cART; a comparative cross-sectional study.
    Jemal M; Shibabaw Molla T; Tiruneh G Medhin M; Chekol Abebe E; Asmamaw Dejenie T
    Ann Med; 2023; 55(2):2295435. PubMed ID: 38118463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risks and Benefits of Dolutegravir- and Efavirenz-Based Strategies for South African Women With HIV of Child-Bearing Potential: A Modeling Study.
    Dugdale CM; Ciaranello AL; Bekker LG; Stern ME; Myer L; Wood R; Sax PE; Abrams EJ; Freedberg KA; Walensky RP
    Ann Intern Med; 2019 May; 170(9):614-625. PubMed ID: 30934067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor-Based Regimens.
    Norwood J; Turner M; Bofill C; Rebeiro P; Shepherd B; Bebawy S; Hulgan T; Raffanti S; Haas DW; Sterling TR; Koethe JR
    J Acquir Immune Defic Syndr; 2017 Dec; 76(5):527-531. PubMed ID: 28825943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment Outcomes of Dolutegravir- Versus Efavirenz-Based Highly Active Antiretroviral Therapy Regimens Among Treatment-Naive People Living With HIV.
    Mahale PR; Patel BS; Kasmani N
    Cureus; 2023 Jun; 15(6):e40139. PubMed ID: 37435267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic Review.
    Rutherford GW; Horvath H
    PLoS One; 2016; 11(10):e0162775. PubMed ID: 27736859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and Safety of Dolutegravir Versus Efavirenz-Based Antiviral Regimen in People Living With HIV-1 in Sichuan Province of China: A Real-World Study.
    Tongtong Y; Shenghua H; Yin W; Lin C; Huanxia L; Chunrong L; Ruifeng Z; Xiaojing Y; Yuan Y; Yuanhong H; Ke Y
    J Acquir Immune Defic Syndr; 2022 Oct; 91(S1):S1-S7. PubMed ID: 36094508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of dolutegravir-based first-line antiretroviral therapy on weight and body mass index among adult people living with HIV on follow up at health facilities in Hawassa city administration, Southern Ethiopia: a retrospective cohort study.
    Hirigo AT; Yilma D; Astatkie A; Debebe Z
    Ann Med; 2023; 55(2):2242250. PubMed ID: 37531412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brief Report: Weight Gain Following ART Initiation in ART-Naïve People Living With HIV in the Current Treatment Era.
    Ruderman SA; Crane HM; Nance RM; Whitney BM; Harding BN; Mayer KH; Moore RD; Eron JJ; Geng E; Mathews WC; Rodriguez B; Willig AL; Burkholder GA; Lindström S; Wood BR; Collier AC; Vannappagari V; Henegar C; Van Wyk J; Curtis L; Saag MS; Kitahata MM; Delaney JAC
    J Acquir Immune Defic Syndr; 2021 Mar; 86(3):339-343. PubMed ID: 33148997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunological, Cognitive, and Psychiatric Outcomes After Initiating Efavirenz- and Dolutegravir-based Antiretroviral Therapy During Acute Human Immunodeficiency Virus Infection.
    Chan P; Yoon B; Colby D; Kroon E; Sacdalan C; Sriplienchan S; Pinyakorn S; Ananworanich J; Valcour V; Vasan S; Hsu D; Phanuphak N; Paul R; Spudich S
    Clin Infect Dis; 2023 Feb; 76(3):e718-e726. PubMed ID: 35687498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative durability of nevirapine versus efavirenz in first-line regimens during the first year of initiating antiretroviral therapy among Swaziland HIV-infected adults.
    Takuva S; Evans D; Zuma K; Okello V; Louwagie G
    Pan Afr Med J; 2013; 15():5. PubMed ID: 23847702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient experiences of switching from Efavirenz- to Dolutegravir-based antiretroviral therapy: a qualitative study in Uganda.
    Twimukye A; Laker M; Odongpiny EAL; Ajok F; Onen H; Kalule I; Kajubi P; Seden K; Owarwo N; Kiragga A; Armstrong-Hough M; Katahoire A; Mujugira A; Lamorde M; Castelnuovo B
    BMC Infect Dis; 2021 Nov; 21(1):1154. PubMed ID: 34774018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mother-to-Child HIV Transmission With In Utero Dolutegravir vs. Efavirenz in Botswana.
    Davey S; Ajibola G; Maswabi K; Sakoi M; Bennett K; Hughes MD; Isaacson A; Diseko M; Zash R; Batlang O; Moyo S; Lockman S; Lichterfeld M; Kuritzkes DR; Makhema J; Shapiro R
    J Acquir Immune Defic Syndr; 2020 Jul; 84(3):235-241. PubMed ID: 32195745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An evaluation of postmarketing reports of hyperglycaemia associated with dolutegravir for treatment of HIV in Eswatini.
    Duga AL; Magongo S; Nhlabatsi S; Ladwar DO; Härmark L; Rolfes L
    AIDS Res Ther; 2022 Nov; 19(1):54. PubMed ID: 36424607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent data on the role of antiretroviral therapy in weight gain and obesity in persons living with HIV.
    Capeau J; Lagathu C; Béréziat V
    Curr Opin HIV AIDS; 2024 Jan; 19(1):14-20. PubMed ID: 38078606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine/dolutegravir, tenofovir disoproxil fumarate/emtricitabine/dolutegravir or tenofovir disoproxil fumarate/emtricitabine/efavirenz.
    Asif S; Baxevanidi E; Hill A; Venter WDF; Fairlie L; Masenya M; Serenata C; Sokhela S; Chandiwana N
    AIDS; 2021 Dec; 35(Suppl 2):S117-S125. PubMed ID: 34261099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study).
    Waitt C; Orrell C; Walimbwa S; Singh Y; Kintu K; Simmons B; Kaboggoza J; Sihlangu M; Coombs JA; Malaba T; Byamugisha J; Amara A; Gini J; Else L; Heiburg C; Hodel EM; Reynolds H; Mehta U; Byakika-Kibwika P; Hill A; Myer L; Lamorde M; Khoo S
    PLoS Med; 2019 Sep; 16(9):e1002895. PubMed ID: 31539371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dolutegravir in real life: Self-reported mental and physical health outcomes after transitioning from efavirenz- to dolutegravir-based antiretroviral therapy in a prospective cohort study in Lesotho.
    Brown JA; Nsakala BL; Mokhele K; Rakuoane I; Muhairwe J; Glass TR; Amstutz A; Tschumi N; Belus JM; Klimkait T; Labhardt ND
    HIV Med; 2023 Feb; 24(2):153-162. PubMed ID: 35730213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.